Approval · Notice of Compliance 37120 · 2026
BLENREP: Notice of Compliance 37120
Issued March 16, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37120
- Date
- March 16, 2026
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the inner labels
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BLENREP | Not yet assigned | — |
Medicinal ingredients
- BELANTAMAB MAFODOTIN 100 MG per VIAL
- BELANTAMAB MAFODOTIN 70 MG per VIAL